What is it? · Chemically converted derivative

What is Mitragynine pseudoindoxyl?

Mitragynine pseudoindoxyl is a distinct kratom-related compound, often abbreviated MGPI or MP. Despite the shared name, it is not the same molecule as mitragynine and should not be confused with a conventional mitragynine extract.

Mitragynine pseudoindoxylMGPI; MP; pseudoindoxyl

Category

Chemically converted derivative

Also called

MGPI; MP; pseudoindoxyl

Key distinction

Ingredient identity and manufacturing process matter more than a trade name.

Mitragynine pseudoindoxyl: advised against.

DEA's published order addresses its potent opioid activity and public-health risks. We advise against products containing it. A marketing description such as kratom-derived does not resolve the exact chemical identity or composition.

From leaf to ingredient

Where does it come from?

Chemically converted retail preparations are grouped with semisynthetic derivatives. Researchers also study biological conversion involving related alkaloids, so the production category should not be read as a claim that the molecule can arise only in a factory.

Read the label

What makes it different?

Extracting mitragynine from leaf and chemically changing it into pseudoindoxyl are different processes. An ingredient panel that says pseudoindoxyl, MGPI or MP identifies a separate compound, rather than another spelling for mitragynine.

What is its legal status?

The August 26, 2026 temporary federal order places mitragynine pseudoindoxyl and covered forms in Schedule I. The later October proposal would use thresholds for MGPI and 7-OH, but that proposal does not itself replace the existing MGPI order. No replacement was verified through November 17, 2026.

Check federal, state and local law

Read the originals

Sources & further reading

Legal sources reviewed: November 17, 2026.

Responsible-use guidance covers interactions, dependence and other precautions.